Evidence map›Paper›PMID 23071682›Full record

ArticlePloS one2012

Targeted genomic integration of a selectable floxed dual fluorescence reporter in human embryonic stem cells.

Jay A Gantz, Nathan J Palpant, Robert E Welikson, Stephen D Hauschka, Charles E Murry, Michael A Laflamme

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Genome editing in cardiovascular diseases.Nature reviews. Cardiology · 2017
    Review
  12. Article
  13. Article
  14. Site-Specific Genome Engineering in Human Pluripotent Stem Cells.International journal of molecular sciences · 2016
    Review
  15. Article
  16. Article
  17. Cardiac tissue engineering and regeneration using cell-based therapy.Stem cells and cloning : advances and applications · 2015
    Review
  18. Pluripotent stem cell derived cardiomyocytes for cardiac repair.Current treatment options in cardiovascular medicine · 2014
    Article
  19. Article
  20. The roles of PDGF in development and during neurogenesis in the normal and diseased nervous system.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jay A GantzDepartment of Bioengineering, Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, United States of America.
Nathan J Palpant
Robert E Welikson
Stephen D Hauschka
Charles E Murry
Michael A Laflamme
University of Washington · US

Funding

Self Renewal and Differentiation of Human Embryonic Stem CellsP01GM081619 · NIGMS · UNIVERSITY OF WASHINGTON · PI REH, THOMAS A · 2007 to 2017
$20.6M
Vascularization and Growth of Human Myocardial GraftsP01HL094374 · NHLBI · UNIVERSITY OF WASHINGTON · PI MINAMI, ELINA · 2010 to 2014
$14.5M
Signalling via Dystrobrevin in Muscular DystrophyP01NS046788 · NINDS · UNIVERSITY OF WASHINGTON · PI FROEHNER, STANLEY C · 2004 to 2013
$12.8M
Engineered Cardiac Morphogenesis-Stem Cells and ScaffoldsR01HL064387 · NHLBI · UNIVERSITY OF WASHINGTON · PI RATNER, BUDDY D · 2006 to 2010
$10.2M
Expansion of cardiac and hematopoietic progenitors by Wnt and NotchU01HL100405 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI EPSTEIN, JONATHAN A., MORRISEY, EDWARD E · 2009 to 2015
$8.1M
Cell-Based Cardiac RepairR01HL084642 · NHLBI · UNIVERSITY OF WASHINGTON · PI MURRY, CHARLES E · 2007 to 2014
$4.9M
Bioengineering Cardiovascular Training GrantT32EB001650 · NIBIB · UNIVERSITY OF WASHINGTON · PI REGNIER, MICHAEL · 2004 to 2019
$3.6M
Striated Muscle Gene Transcription and Regulatory Gene Cassettes for Gene TherapyR01AR018860 · NIAMS · UNIVERSITY OF WASHINGTON · PI HAUSCHKA, STEPHEN DENISON · 1986 to 2012
$3.4M
NHLBI NIH HHS P01 HL094374NHLBI NIH HHS P01-HL094374NHLBI NIH HHS R01 HL064387NHLBI NIH HHS R01-HL064387NHLBI NIH HHS R01 HL084642NHLBI NIH HHS R01-HL084642NHLBI NIH HHS U01 HL100405NHLBI NIH HHS U01-HL100405NIAMS NIH HHS R01 AR018860NIAMS NIH HHS R01-AR18860NIBIB NIH HHS T32 EB001650NIGMS NIH HHS P01 GM081619NIGMS NIH HHS P01-GM81619NINDS NIH HHS 1P01-NS046788NINDS NIH HHS P01 NS046788
6 · The paper itself

Abstract

The differentiation of pluripotent stem cells involves transition through a series of specific cell states. To understand these cell fate decisions, the field needs improved genetic tools for the labeling, lineage tracing and selection of specific cell types from heterogeneous differentiating populations, particularly in the human embryonic stem cell (hESC) system. We used zinc finger nuclease technology to stably insert a unique, selectable, floxed dual-fluorescence reporter transgene into the AAVS1 locus of RUES2 hESCs. This "stoplight" transgene, mTmG-2a-Puro, strongly expresses membrane-localized tdTomato red fluorescent protein until Cre-dependent recombination causes a switch to expression of membrane-localized enhanced green fluorescent protein (eGFP) and puromycin resistance. First, to validate this system in undifferentiated cells, we transduced transgenic hESCs with a lentiviral vector driving constitutive expression of Cre and observed the expected phenotypic switch. Next, to demonstrate its utility in lineage-specific selection, we transduced differentiated cultures with a lentiviral vector in which the striated muscle-specific CK7 promoter drives Cre expression. This yielded near-homogenous populations of eGFP(+) hESC-derived cardiomyocytes. The mTmg-2a-Puro hESC line described here represents a useful new tool for both in vitro fate mapping studies and the selection of useful differentiated cell types.

Indexed as

Cell DifferentiationCells, CulturedEmbryonic Stem CellsFlow CytometryFluorescent Antibody TechniqueGene TargetingGenetic EngineeringGenetic VectorsGreen Fluorescent ProteinsHumansLentivirusLuminescent ProteinsMyocytes, CardiacTime FactorsTransgenesZinc FingersGreen Fluorescent ProteinsLuminescent Proteins

Identifiers

PMID23071682
PMCPMC3468579
OpenAlexW1995046480

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.